Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)

NCT03576378 is registered in ClinicalTrials.gov with Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea as lead sponsor.

NCT NCT03576378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03576378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)
Lead sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 8, 2018
Completion date
October 30, 2024
Enrollment
41 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma